162 related articles for article (PubMed ID: 7913705)
1. Multidrug resistance. Clinical opportunities in diagnosis and circumvention.
Chan HS; DeBoer G; Thorner PS; Haddad G; Gallie BL; Ling V
Hematol Oncol Clin North Am; 1994 Apr; 8(2):383-410. PubMed ID: 7913705
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance in pediatric malignancies.
Chan HS; DeBoer G; Haddad G; Gallie BL; Ling V
Hematol Oncol Clin North Am; 1995 Apr; 9(2):275-318. PubMed ID: 7642465
[TBL] [Abstract][Full Text] [Related]
3. Multidrug drug resistance in pediatric sarcomas.
Chan HS; DeBoer G; Haddad G; Ling V
Hematol Oncol Clin North Am; 1995 Aug; 9(4):889-908. PubMed ID: 7490247
[TBL] [Abstract][Full Text] [Related]
4. A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Haddad G; Thorner PS; Bradley G; Dalton WS; Ling V; Chan HS
Lab Invest; 1994 Oct; 71(4):595-603. PubMed ID: 7967514
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
7. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
Ihnat MA; Lariviere JP; Warren AJ; La Ronde N; Blaxall JR; Pierre KM; Turpie BW; Hamilton JW
Clin Cancer Res; 1997 Aug; 3(8):1339-46. PubMed ID: 9815817
[TBL] [Abstract][Full Text] [Related]
8. Molecular targets in oncology: implications of the multidrug resistance gene.
Lum BL; Gosland MP; Kaubisch S; Sikic BI
Pharmacotherapy; 1993; 13(2):88-109. PubMed ID: 8097038
[TBL] [Abstract][Full Text] [Related]
9. The inability of the mouse mdr2 gene to confer multidrug resistance is linked to reduced drug binding to the protein.
Buschman E; Gros P
Cancer Res; 1994 Sep; 54(18):4892-8. PubMed ID: 7915194
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance mediated by P-glycoprotein in haematological malignancies.
Pasman PC; Schouten HC
Neth J Med; 1993 Jun; 42(5-6):218-31. PubMed ID: 8104318
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells.
Savas B; Cole SP; Akoglu TF; Pross HF
Nat Immun; 1992; 11(4):177-92. PubMed ID: 1358293
[TBL] [Abstract][Full Text] [Related]
12. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
13. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
[TBL] [Abstract][Full Text] [Related]
14. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by RU 486.
Gruol DJ; Zee MC; Trotter J; Bourgeois S
Cancer Res; 1994 Jun; 54(12):3088-91. PubMed ID: 7911394
[TBL] [Abstract][Full Text] [Related]
16. Modulators of multidrug resistance. Preclinical studies.
Ford JM
Hematol Oncol Clin North Am; 1995 Apr; 9(2):337-61. PubMed ID: 7642467
[TBL] [Abstract][Full Text] [Related]
17. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance: clinical relevance in acute leukemia.
List AF
Oncology (Williston Park); 1993 Oct; 7(10):23-8, 32; discussion 32, 35-8. PubMed ID: 7902728
[TBL] [Abstract][Full Text] [Related]
20. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
